Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort
The study aimed to investigate comorbidities, major adverse respiratory events, and mortality in patients with idiopathic pulmonary fibrosis (IPF). We established an IPF cohort and a comparative cohort matched for sex, age, and the date of IPF diagnosis. We recorded the most frequent comorbidities,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-11-01
|
| Series: | Open Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/med-2023-0852 |
| _version_ | 1797628642674606080 |
|---|---|
| author | Wang Ying-Tso Shen Te-Chun Lin Cheng-Li Tu Chih-Yen Hsia Te-Chun Hsu Wu-Huei |
| author_facet | Wang Ying-Tso Shen Te-Chun Lin Cheng-Li Tu Chih-Yen Hsia Te-Chun Hsu Wu-Huei |
| author_sort | Wang Ying-Tso |
| collection | DOAJ |
| description | The study aimed to investigate comorbidities, major adverse respiratory events, and mortality in patients with idiopathic pulmonary fibrosis (IPF). We established an IPF cohort and a comparative cohort matched for sex, age, and the date of IPF diagnosis. We recorded the most frequent comorbidities, the proportions, and time durations to the episode of major adverse respiratory events and death. Both cohorts were followed up to the end of 2016. We included 921 patients in the IPF cohort and 3,677 individuals in the comparative cohort. Comorbidities associated with IPF included pulmonary hypertension, chronic obstructive pulmonary disease, heart failure, asthma, and gastroesophageal reflux disease. The IPF cohort was more likely to have pneumonia (47.6 vs 12.0%), acute respiratory failure (17.8 vs 4.30%), chronic respiratory failure (4.23 vs 0.63%), and death (36.3 vs 15.0%) than the comparative cohort. The time durations to the first episode of pneumonia, acute respiratory failure, chronic respiratory failure, and death were 2.09 ± 2.98, 3.12 ± 3.62, 3.20 ± 4.03, and 3.27 ± 3.03 years in the IPF cohort. In conclusion, patients with IPF had significant comorbidities, particularly pulmonary and cardiovascular comorbidities. The duration from diagnosis to the major adverse respiratory events or death was short. |
| first_indexed | 2024-03-11T10:41:41Z |
| format | Article |
| id | doaj.art-5c612fda304441cb9075ebb72fa633cf |
| institution | Directory Open Access Journal |
| issn | 2391-5463 |
| language | English |
| last_indexed | 2024-03-11T10:41:41Z |
| publishDate | 2023-11-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Medicine |
| spelling | doaj.art-5c612fda304441cb9075ebb72fa633cf2023-11-14T08:29:50ZengDe GruyterOpen Medicine2391-54632023-11-0118179580610.1515/med-2023-0852Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohortWang Ying-Tso0Shen Te-Chun1Lin Cheng-Li2Tu Chih-Yen3Hsia Te-Chun4Hsu Wu-Huei5Department of Laboratory Medicine, China Medical University Hospital, Taichung, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, No. 2 Yu-De Road, Taichung404, TaiwanManagement Office for Health Data, China Medical University Hospital, Taichung, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, No. 2 Yu-De Road, Taichung404, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, No. 2 Yu-De Road, Taichung404, TaiwanSchool of Medicine, China Medical University, Taichung, TaiwanThe study aimed to investigate comorbidities, major adverse respiratory events, and mortality in patients with idiopathic pulmonary fibrosis (IPF). We established an IPF cohort and a comparative cohort matched for sex, age, and the date of IPF diagnosis. We recorded the most frequent comorbidities, the proportions, and time durations to the episode of major adverse respiratory events and death. Both cohorts were followed up to the end of 2016. We included 921 patients in the IPF cohort and 3,677 individuals in the comparative cohort. Comorbidities associated with IPF included pulmonary hypertension, chronic obstructive pulmonary disease, heart failure, asthma, and gastroesophageal reflux disease. The IPF cohort was more likely to have pneumonia (47.6 vs 12.0%), acute respiratory failure (17.8 vs 4.30%), chronic respiratory failure (4.23 vs 0.63%), and death (36.3 vs 15.0%) than the comparative cohort. The time durations to the first episode of pneumonia, acute respiratory failure, chronic respiratory failure, and death were 2.09 ± 2.98, 3.12 ± 3.62, 3.20 ± 4.03, and 3.27 ± 3.03 years in the IPF cohort. In conclusion, patients with IPF had significant comorbidities, particularly pulmonary and cardiovascular comorbidities. The duration from diagnosis to the major adverse respiratory events or death was short.https://doi.org/10.1515/med-2023-0852idiopathic pulmonary fibrosiscomorbidityprogressionprognosis |
| spellingShingle | Wang Ying-Tso Shen Te-Chun Lin Cheng-Li Tu Chih-Yen Hsia Te-Chun Hsu Wu-Huei Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort Open Medicine idiopathic pulmonary fibrosis comorbidity progression prognosis |
| title | Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort |
| title_full | Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort |
| title_fullStr | Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort |
| title_full_unstemmed | Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort |
| title_short | Real-world practice of idiopathic pulmonary fibrosis: Results from a 2000–2016 cohort |
| title_sort | real world practice of idiopathic pulmonary fibrosis results from a 2000 2016 cohort |
| topic | idiopathic pulmonary fibrosis comorbidity progression prognosis |
| url | https://doi.org/10.1515/med-2023-0852 |
| work_keys_str_mv | AT wangyingtso realworldpracticeofidiopathicpulmonaryfibrosisresultsfroma20002016cohort AT shentechun realworldpracticeofidiopathicpulmonaryfibrosisresultsfroma20002016cohort AT linchengli realworldpracticeofidiopathicpulmonaryfibrosisresultsfroma20002016cohort AT tuchihyen realworldpracticeofidiopathicpulmonaryfibrosisresultsfroma20002016cohort AT hsiatechun realworldpracticeofidiopathicpulmonaryfibrosisresultsfroma20002016cohort AT hsuwuhuei realworldpracticeofidiopathicpulmonaryfibrosisresultsfroma20002016cohort |